Helperby Secures 75 Million Capital Commitment from GEM as Company Seeks to Go Public

Helperby Therapeutics Group Limited (“Helperby”) is a private pharmaceutical company focussed on developing multiple new antibiotic products to counter the global spread of Anti Microbial Resistance (“AMR”). Helperby has signed an agreement with GEM Global Yield LLC SCS (“GEM”), a Luxembourg-based private alternative investment group for an investment of up to $75 million within 3 years of any public listing.

Under the agreement, GEM commits to providing HELPERBY with a share subscription facility of up to 75 million for a 36-month term following public listing of HELPERBY shares. HELPERBY will remain in control of the timing and, within certain limits, the maximum amount of each individual drawdown under this facility and has no minimum drawdown obligation. Concurrent with a public listing of HELPERBY, the company will issue warrants to GEM to purchase additional shares in HELPERBY.
“This represents an important step in our plans to bring multiple new antibiotic combinations to market globally. GEM have well known and global expertise in health and technology and we are delighted they recognise the value our portfolio would bring” said James Phipson, Helperby Chairman and CEO.

GEM commented “Our experts recognised the unique transformative approach Helperby offered and understood the opportunity to bring a portfolio of new antibiotics to the market, quickly, cheaply and profitably.

Each product is a designed combination of existing approved antibiotics which act synergistically, increasing the effects beyond either single drug alone. This approach is proven against malaria and AIDS/HIV, with several of the world’s top-selling products being multiple drug combinations. Combinations greatly reduce the risk, lead time for approvals, and cost of clinical trials by using already-approved drugs. They greatly increase the longevity of the products and associated patents, as new combinations are discovered, and existing ones varied by additional synergistic drugs.”

J Phipson continued “Helperby has three products ready for immediate clinical trials, all of which target World Health Organisation Critical or High Priority Pathogens, initially with IV products for severe hospitalised patients but also with broader indications and oral products in Helperby’s portfolio. Our broader IP portfolio and development pipeline will ensure a continual supply of new antibiotics for many years to come.”

About Helperby:

Helperby Therapeutics is based in London, Dublin and Bedford NH(USA) and was spun out from the Medical School at London’s St George’s Hospital, which forms part of Britain’s National Health Service. The Company’s Founder, Professor Sir Anthony Coates is a global authority on AMR, a leader on global efforts to combat AMR over many years and a lecturer on these subjects at the medical school of City St George's, University of London. More information can be found at www.helperby.com.

About GEM

Global Emerging Markets (“GEM”) is a $3.4 billion, alternative investment group with offices in Paris, New York and Nassau (Bahamas) GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 600 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information: http://www.gemny.com